Sumitomo Dainippon Pharma : ESG Meeting (Discussion with Investors)

ESG Meeting (Discussion with Investors)

December 8, 2021

Sumitomo Dainippon Pharma Co., Ltd.

Disclaimer Regarding Forward-looking Statements

This material contains forecasts, projections, targets, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.

Accordingly, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.

Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Group holds approximately 54% of the outstanding shares of Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant. For more information on Myovant, please visit https://www.myovant.com/.

1

Today's Agenda

1.	Application for Selection of "Prime Market"/Complying with
	the Revised Japan's Corporate Governance Code	Representative Director, President and CEO	Hiroshi Nomura
2.	Setting KPIs for Materiality/Initiatives for Environment	Executive Officer	Atsuko Higuchi
3.	Panel Discussion Panelists:	Member, Board of Directors, Chairman	Masayo Tada
		Representative Director, President and CEO	Hiroshi Nomura
		Representative Director, Executive Vice President	Toru Kimura
		Member, Board of Directors (Outside)	Yutaka Atomi
		Member, Board of Directors (Outside)	Saeko Arai
		Member, Board of Directors (Outside)	Nobuhiro Endo
		Member, Board of Directors (Outside)	Minoru Usui
		Executive Officer		Atsuko Higuchi
	Facilitator:	RIDEAL CEO		Mariko Mishiro

4. Q&As

2

Application for Selection of "Prime Market"/

Complying with the Revised Japan's Corporate Governance Code

Hiroshi Nomura

Representative Director, President and CEO

3

Application for Selection of "Prime Market"

Application for Selection of "Prime Market"

At a meeting of the Board of Directors (BoD) held on November 30, 2021, the Company's BoD resolved to select and apply for listing on the Prime Market, Tokyo Stock Exchange new market segments

• Next step

• We will make continued efforts to achieve the high-level governance required of companies listed on the Prime Market by complying with, for example, the revised Japan's Corporate Governance Code
• We will work to achieve sustained growth and improve corporate value over the mid- to long-term through constructive dialogues with investors and other means

4